Company intelligence / Profile preview

Bionamics GmbH

Ownership: Private
Employees: ~3
Development stage: Phase 2

Overview

Bionamics was an asset management company that focused on translating academic innovations into attractive assets for the biotech and pharmaceutical industry. It managed projects including the NEU² consortium for neurodegenerative diseases.

Therapeutic areas: Neurology
Industry: Investors

Drug pipeline

1 asset

BNC210

Phase 2

Indications: Social Anxiety Disorder, Post-Traumatic Stress Disorder

Partnerships

NEU² consortium

Beyond the preview

Go deeper on Bionamics GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionamics GmbH.

Explore the full profile